Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will examine the influence of donor and recipient pharmacogenetics (PG), drug pharmacokinetics (PK), and T cell phenotypes and how it may permit a tailored dosing strategy to improve the therapeutic index of post-transplant cyclophosphamide (PTCy) and optimize the graft versus tumor effect, while minimizing acute and chronic graft versus host disease (GVHD).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Zgoda na udział w badaniu i dostęp do informacji medycznych
- •Przygotowanie do przeszczepu komórek krwiotwórczych z dawcą spokrewnionym, niespokrewnionym lub półidentycznym
- •Planowane podanie cyklofosforamidu po przeszczepieniu
- •Zdolność do zrozumienia i wykonywania procedur badania
✗ Disqualifies
- •Stosowanie eksperymentalnych leków w ciągu 30 dni przed rozpoczęciem leczenia
- •Brak zgody dawcy na udział w badaniu (dotyczy przeszczepu od rodzica lub spokrewnionego)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Levine Cancer Institute
Charlotte, United States
Trial contact
Elizabeth Parke
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.